Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases

被引:2
|
作者
Stanel, Stefan Cristian [1 ,2 ]
Rivera-Ortega, Pilar [1 ]
机构
[1] Univ Manchester, Wythenshawe Hosp, NHS Fdn Trust,North West Lung Ctr, Interstitial Lung Dis ILD Unit, Manchester, England
[2] Univ Manchester, Fac Biol, Med & Hlth, Manchester, England
关键词
progressive fibrosing interstitial lung disease; progressive pulmonary fibrosis; interstitial lung disease; idiopathic pulmonary fibrosis; PF-ILD; PPF; CHRONIC HYPERSENSITIVITY PNEUMONITIS; IDIOPATHIC PULMONARY-FIBROSIS; TELOMERE LENGTH; MULTIDISCIPLINARY;
D O I
10.3389/fmed.2023.1114722
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progressive fibrosing interstitial lung diseases (PF-ILDs) represent a group of conditions of both known and unknown origin which continue to worsen despite standard treatments, leading to respiratory failure and early mortality. Given the potential to slow down progression by initiating antifibrotic therapies where appropriate, there is ample opportunity to implement innovative strategies for early diagnosis and monitoring with the goal of improving clinical outcomes. Early diagnosis can be facilitated by standardizing ILD multidisciplinary team (MDT) discussions, implementing machine learning algorithms for chest computed-tomography quantitative analysis and novel magnetic-resonance imaging techniques, as well as measuring blood biomarker signatures and genetic testing for telomere length and identification of deleterious mutations in telomere-related genes and other single-nucleotide polymorphisms (SNPs) linked to pulmonary fibrosis such as rs35705950 in the MUC5B promoter region. Assessing disease progression in the post COVID-19 era also led to a number of advances in home monitoring using digitally-enabled home spirometers, pulse oximeters and other wearable devices. While validation for many of these innovations is still in progress, significant changes to current clinical practice for PF-ILDs can be expected in the near future.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] From Bench to Bedside: Nintedanib for Progressive Fibrosing Interstitial Lung Diseases
    Garlick, Kristopher
    Wollin, Lutz
    Distler, Joerg
    Stowasser, Susanne
    Schlenker-Herceg, Rozsa
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 822 - 822
  • [32] FROM BENCH TO BEDSIDE: NINTEDANIB FOR PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES
    Wollin, L.
    Distler, J.
    Redente, E.
    Riches, D.
    Stowasser, S.
    Schlenker-Herceg, R.
    RESPIROLOGY, 2019, 24 : 171 - 171
  • [33] Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
    Copeland, Carla R.
    Lancaster, Lisa H.
    FRONTIERS IN MEDICINE, 2021, 8
  • [34] Improving Palliative Care Referrals in Progressive Fibrosing Interstitial Lung Diseases
    English, L. V. Bocanegra
    Puthumana, R. M.
    Sosa, M. A.
    Khawand-Azoulai, M.
    Gershengorn, H. B.
    Patel, S.
    Vehar, S.
    Koch, A. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [35] Reply to comment on "The natural history of progressive fibrosing interstitial lung diseases"
    Brown, Kevin K.
    Schlenker-Herceg, Rozsa
    Wells, Athol U.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (06)
  • [36] Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
    Fischer, Aryeh
    Distler, Joerg
    CLINICAL RHEUMATOLOGY, 2019, 38 (10) : 2673 - 2681
  • [37] Radiological diagnosis of fibrosing interstitial lung diseases: innovations and controversies
    Carlicchi, E.
    Harari, S.
    Caminati, A.
    Fughelli, P.
    Zompatori, M.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2020, 24 (11) : 1156 - +
  • [38] Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype
    Inoue, Yoshikazu
    Kaner, Robert J.
    Guiot, Julien
    Maher, Toby M.
    Tomassetti, Sara
    Moiseev, Sergey
    Kuwana, Masataka
    Brown, Kevin K.
    CHEST, 2020, 158 (02) : 646 - 659
  • [39] Management of Fibrosing Interstitial Lung Diseases
    Maher, Toby M.
    Wuyts, Wim
    ADVANCES IN THERAPY, 2019, 36 (07) : 1518 - 1531
  • [40] Management of Fibrosing Interstitial Lung Diseases
    Toby M. Maher
    Wim Wuyts
    Advances in Therapy, 2019, 36 : 1518 - 1531